Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 6/2008

Open Access 01-11-2008

The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice

Authors: Calliope A. Dendrou, Linda S. Wicker

Published in: Journal of Clinical Immunology | Issue 6/2008

Login to get access

Abstract

Although the interleukin-2 (IL-2)/IL-2R signaling pathway has been the focus of numerous studies, certain aspects of its molecular regulation are not well characterized, especially in non-T cells, and a more complete understanding of the pathway is necessary to discern the functional basis of the genetic association between the IL-2-IL-21 and IL-2RA/CD25 gene regions and T1D in humans. Genetic variation in these regions may promote T1D susceptibility by influencing transcription and/or splicing and, hence, IL-2 and IL-2RA/CD25 expression at the protein level in different immune cell subsets; thus, there is a need to establish links between the genetic variation and immune cell phenotypes and functions in humans, which can be further investigated and validated in mouse models. The detection and characterization of genetically determined immunophenotypes should aid in elucidating disease mechanisms and may enable future monitoring of disease initiation and progression in prediabetic subjects and of responses to therapeutic intervention.
Literature
1.
Davies JL, Kawaguchi Y, Bennett ST, et al. A genome-wide search for human type-1 diabetes susceptibility genes. Nature. 1994;371:130–6.PubMedCrossRef
2.
Field LL. Genetic linkage and association studies of Type I diabetes: challenges and rewards. Diabetologia. 2002;45:21–35.PubMedCrossRef
3.
4.
Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol. 1995;13:179–200.PubMedCrossRef
5.
Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221–9.PubMedCrossRef
6.
Gottlieb PA, Eisenbarth GS. Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med. 1998;49:391–405.PubMedCrossRef
7.
Burton PR, Clayton DG, Cardon LR, et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.CrossRef
8.
Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857–64.PubMedCrossRef
9.
Barratt BJ, Payne F, Lowe CE, et al. Remapping the insulin gene/IDDM2 locus in type 1 diabetes. Diabetes. 2004;53:1884–9.PubMedCrossRef
10.
Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–11.PubMedCrossRef
11.
Begovich AB, Carlton VEH, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75:330–7.PubMedCrossRef
12.
Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36:337–8.PubMedCrossRef
13.
Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes. 2004;53:3020–3.PubMedCrossRef
14.
Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007;39:1074–82.PubMedCrossRef
15.
Vella A, Cooper JD, Lowe CE, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet. 2005;76:773–9.PubMedCrossRef
16.
Lyons PA, Armitage N, Argentina F, et al. Congenic mapping of the type 1 diabetes locus, ldd3, to a 780-kb region of mouse chromosome 3: Identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res. 2000;10:446–53.PubMedCrossRef
17.
Podolin PL, Wilusz MB, Cubbon RM, et al. Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine. 2000;12:477–82.PubMedCrossRef
18.
Wicker LS, Clark J, Fraser HI, et al. Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun. 2005;25:29–33.PubMed
19.
Yamanouchi J, Rainbow D, Serra P, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet. 2007;39:329–37.PubMedCrossRef
20.
del Rio R, Noubade R, Subramanian M, et al. SNPs upstream of the minimal promoter control IL-2 expression and are candidates for the autoimmune disease-susceptibility locus Aod2/Idd3/Eae3. Genes and Immunity. 2008;9:115–21.PubMedCrossRef
21.
Chapman JM, Cooper JD, Todd JA, et al. Detecting disease associations due to linkage disequilibrium using haplotype tags: A class of tests and the determinants of statistical power. Hum Hered. 2003;56:18–31.PubMedCrossRef
22.
Johnson GCL, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet. 2001;29:233–7.PubMedCrossRef
23.
Qu HQ, Montpetit A, Ge B, et al. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes. 2007;56:1174–6.PubMedCrossRef
24.
Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 2006;7:349–66.CrossRef
25.
Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31:89–97.PubMedCrossRef
26.
Roh TY, Ngau WC, Cui KR, et al. High-resolution genome-wide mapping of histone modifications. Nat Biotechnol. 2004;22:1013–6.PubMedCrossRef
27.
Kramer S, Schimpl A, Hunig T. Immunopathology of interleukin (IL)2-deficient mice - thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J Exp Med. 1995;182:1769–76.PubMedCrossRef
28.
Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253–61.PubMedCrossRef
29.
Schorle H, Holtschke T, Hunig T, et al. Development and function of T-cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 1991;352:621–4.PubMedCrossRef
30.
Willerford DM, Chen JZ, Ferry JA, et al. Interleukin-2 receptor-alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995;3:521–30.PubMedCrossRef
31.
Teuscher C, Wardell BB, Lunceford JK, et al. Aod2, the locus controlling development of atrophy in neonatal thymectomy-induced autoimmune ovarian dysgenesis, co-localizes with Il2, Fgfb, and Idd3. J Exp Med. 1996;183:631–7.PubMedCrossRef
32.
Encinas JA, Wicker LS, Peterson LB, et al. QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. Nat Genet. 1999;21:158–60.PubMedCrossRef
33.
Boulard O, Fluteau G, Eloy L, et al. Genetic analysis of autoimmune sialadenitis in nonobese diabetic mice: A major susceptibility region on chromosome 1. J Immunol. 2002;168:4192–201.PubMed
34.
Cha S, Nagashima H, Brown VB, et al. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren’s syndrome) on a healthy murine background. Arthritis Rheum. 2002;46:1390–8.PubMedCrossRef
35.
Pearson T, Weiser P, Markees TG, et al. Islet allograft survival induced by costimulation blockade in NOD mice is controlled by allelic variants of Idd3. Diabetes. 2004;53:1972–8.PubMedCrossRef
36.
Gordon EJ, Wicker LS, Peterson LB, et al. Autoimmune diabetes and resistance to xenograft transplantation tolerance in NOD mice. Diabetes. 2005;54:107–15.PubMedCrossRef
37.
Martinez X, Kreuwel HTC, Redmond WL, et al. CD8(+) T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles. J Immunol. 2005;175:1677–85.PubMed
38.
van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet. 2007;39:827–9.PubMedCrossRef
39.
Zhernakova A, Alizadeh BZ, Bevova M, et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet. 2007;81:1284–8.PubMedCrossRef
40.
Brand OJ, Lowe CE, Heward JM, et al. Association of the interleukin-2 receptor alpha (IL-2R alpha)/CD25 gene region with Graves’ disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf). 2007;66:508–12.
41.
Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851–62.PubMedCrossRef
42.
Caudy AA, Reddy ST, Chatila T, et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol. 2007;119:482–7.PubMedCrossRef
43.
Sharfe N, Dadi HK, Shahar M, et al. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci USA. 1997;94:3168–71.PubMedCrossRef
44.
Kozyrev SV, Abelson AK, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008;40:211–6.PubMedCrossRef
45.
Leonard WJ, Depper JM, Crabtree GR, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature. 1984;311:626–31.PubMedCrossRef
46.
Leonard WJ, Kronke M, Peffer NJ, et al. Interleukin-2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci USA. 1985;82:6281–5.PubMedCrossRef
47.
Neeper MP, Kuo LM, Kiefer MC, et al. Structure-function relationships for the IL-2 receptor system. 3. Tac protein missing amino-acids 102 to 173 (exon 4) is unable to bind IL-2 - detection of spliced protein after L-cell transfection. J Immunol 1987;138:3532–8.PubMed
48.
Horiuchi S, Koyanagi Y, Tanaka Y, et al. Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism. Immunology. 1997;91:28–34.PubMedCrossRef
49.
50.
Tsytsikov VN, Yurovsky VV, Atamas SP, et al. Identification and characterization of two alternative splice variants of human interleukin-2. J Biol Chem. 1996;271:23055–60.PubMedCrossRef
51.
Minami Y, Kono T, Miyazaki T, et al. The IL-2 receptor complex - its structure, function, and target genes. Annu Rev Immunol. 1993;11:245–68.PubMedCrossRef
52.
Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Advances in Immunology. 1998;70 70:1–81.PubMedCrossRef
53.
Rickert M, Wang XQ, Boulanger MJ, et al. The structure of interleukin-2 complexed with its alpha receptor. Science. 2005;308:1477–80.PubMedCrossRef
54.
Norman DG, Barlow PN, Baron M, et al. 3-dimensional structure of a complement control protein module in solution. J Mol Biol. 1991;219:717–25.PubMedCrossRef
55.
Shackelford DA, Trowbridge IS. Evidence for 2 extracellular domains in the human interleukin-2 receptor - Localization of IL-2 binding. EMBO J. 1986;5:3275–80.PubMed
56.
Stauber DJ, Debler EW, Horton PA, et al. Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci USA. 2006;103:2788–93.PubMedCrossRef
57.
Wang XQ, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma(c) receptors. Science. 2005;310:1159–63.PubMedCrossRef
58.
Lin JX, Mietz J, Modi WS, et al. Cloning of human Stat5B - Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem. 1996;271:10738–44.PubMedCrossRef
59.
Ellery JM, Nicholls PJ. Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev. 2002;13:27–40.PubMedCrossRef
60.
Kovanen PE, Young L, Al-Shami A, et al. Global analysis of IL-2 target genes: identification of chromosomal clusters of expressed genes. Int Immunol. 2005;17:1009–21.PubMedCrossRef
61.
62.
Eicher DM, Waldmann TA. IL-2R alpha on one cell can present IL-2 to IL-2R beta/gamma(c) on another cell to augment IL-2 signaling. J Immunol. 1998;161:5430–7.PubMed
63.
Mier JW, Gallo RC. Purification and some characteristics of human T-cell growth-factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci USA. 1980;77:6134–8.PubMedCrossRef
64.
Malek TR, Yu AX, Scibelli P, et al. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J Immunol. 2001;166:1675–83.PubMed
65.
Lin JX, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 1997;8:313–32.PubMedCrossRef
66.
Gong DP, Malek TR. Cytokine-dependent blimp-1 expression in activated T cells inhibits IL-2 production. J Immunol. 2007;178:242–52.PubMed
67.
Villarino AV, Tato CM, Stumhofer JS, et al. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med. 2007;204:65–71.PubMedCrossRef
68.
69.
Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665–74.PubMedCrossRef
70.
Dooms H, Wolslegel K, Lin P, et al. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med. 2007;204:547–57.PubMedCrossRef
71.
Leung DT, Morefield S, Willerford DM. Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo. J Immunol. 2000;164:3527–34.PubMed
72.
Bachmann MF, Wolint P, Walton S, et al. Differential role of IL-2R signaling for CD8(+) T cell responses in acute and chronic viral infections. Eur J Immunol. 2007;37:1502–12.PubMedCrossRef
73.
Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8(+) memory T cells. Nature. 2006;441:890–3.PubMedCrossRef
74.
Sakaguchi S. Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;2:531–62.CrossRef
75.
Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.PubMedCrossRef
76.
Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389–400.PubMed
77.
Toda A, Piccirillo CA. Development and function of naturally occurring CD4+CD25+ regulatory T cells. J Leukoc Biol. 2006;80:458–70.PubMedCrossRef
78.
Sakaguchi S, Sakaguchi N, Asano M, et al. Immunological self-tolerance maintained by activated T-cells expressing IL-2 receptor alpha-chains (CD25) - Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.PubMed
79.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.PubMedCrossRef
80.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.PubMedCrossRef
81.
Khattri R, Cox T, Yasayko SA, et al. An essential role for Scurfin in CD4(+)CD25(+) T regulatory cells. Nat Immunol. 2003;4:337–42.PubMedCrossRef
82.
Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–1.PubMedCrossRef
83.
Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol. 2003;15:430–5.PubMedCrossRef
84.
Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18–20.PubMedCrossRef
85.
Chatila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000;106:R75–81.PubMedCrossRef
86.
Su L, Creusot RJ, Gallo EM, et al. Murine CD4(+) CD25(+) regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J Immunol. 2004;173:4994–5001.PubMed
87.
Ono M, Yaguchi H, Ohkura N, et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 2007;446:685–9.PubMedCrossRef
88.
Wu YQ, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006;126:375–87.PubMedCrossRef
89.
Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4(+)CD25(+) immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–40.PubMedCrossRef
90.
Tang QZ, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4(+)CD25(+). J Immunol. 2003;171:3348–52.PubMed
91.
Tai XG, Cowan M, Feigenbaum L, et al. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol. 2005;6:152–62.PubMedCrossRef
92.
Bayer AL, Yu AX, Malek TR. Function of the IL-2R for thymic and peripheral CD4(+)CD25(+) Foxp3(+) T regulatory cells. J Immunol. 2007;178:4062–71.PubMed
93.
Liston A, Siggs OM, Goodnow CC. Tracing the action of IL-2 in tolerance to islet-specific antigen. Immunol Cell Biol. 2007;85:338–42.PubMedCrossRef
94.
Jaeckel E, Kretschmer K, Apostolou I, et al. Instruction of Treg commitment in peripheral T cells is suited to reverse autoimmunity. Semin Immunol. 2006;18:89–92.PubMedCrossRef
95.
Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142–51.PubMedCrossRef
96.
Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723–35.PubMedCrossRef
97.
Green EA, Gorelik L, McGregor CM, et al. CD4(+)CD25(+) T regulatory cells control anti-islet CD8(+) T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA. 2003;100:10878–83.PubMedCrossRef
98.
Herman AE, Freeman GJ, Mathis D, et al. CD4(+)CD25(+) T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 2004;199:1479–89.PubMedCrossRef
99.
Chen ZB, Herman AE, Matos M, et al. Where CD4(+) CD25(+) T reg cells impinge on autoimmune diabetes. J Exp Med. 2005;202:1387–97.PubMedCrossRef
100.
Tritt M, Sgouroudis E, d’Hennezel E, et al. Functional waning of naturally occurring CD4(+) regulatory T-Cells contributes to the onset of autoimmune diabetes. Diabetes. 2008;57:113–23.PubMedCrossRef
101.
Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687–97.PubMedCrossRef
102.
Shi FD, Flodstrom M, Balasa B, et al. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA. 2001;98:6777–82.PubMedCrossRef
103.
Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002;109:131–40.PubMed
104.
Brusko TM, Wasserfall CH, Clare-Salzler MJ, et al. Functional defects and the influence of age on the frequency of CD4(+)CD25(+) T-Cells in type 1 diabetes. Diabetes. 2005;54:1407–14.PubMedCrossRef
105.
Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54:92–9.PubMedCrossRef
106.
Putnam AL, Vendrame F, Dotta F, et al. CD4+CD25(high) regulatory T cells in human autoimmune diabetes. J Autoimmun. 2005;24:55–62.PubMedCrossRef
107.
Tree TIM, Roep BO, Peakman M. A mini meta-analysis of studies on CD4(+)CD25(+) T cells in human type 1 diabetes—Report of the Immunology of Diabetes Society T Cell Workshop. Immunology of Diabetes IV: Progress in Our Understanding. 2006;1079:9–18.
108.
Brusko T, Wasserfall C, McGrail K, et al. No alterations in the frequency of FOXP3(+) regulatory T-cells in type 1 diabetes. Diabetes. 2007;56:604–12.PubMedCrossRef
109.
Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4(+)CD25(hi)Foxp3(+) regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest. 2006;116:2423–33.PubMedCrossRef
110.
Roncador G, Brown PJ, Maestre L, et al. Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. Eur J Immunol. 2005;35:1681–91.PubMedCrossRef
111.
Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25(high) regulatory cells in human peripheral blood. J Immunol. 2001;167:1245–53.PubMed
112.
Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol. 2002;169:6210–7.PubMed
113.
Gregori S, Giarratana N, Smiroldo S, et al. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol. 2003;171:4040–7.PubMed
114.
Pop SM, Wong CP, Culton DA, et al. Single cell analysis shows decreasing FoxP3 and TGF beta 1 coexpressing CD4(+)CD25(+) regulatory T cells during autoimmune diabetes. J Exp Med. 2005;201:1333–46.PubMedCrossRef
115.
You S, Belghith M, Cobbold S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes. 2005;54:1415–22.PubMedCrossRef
116.
Waithman J, Gebhardt T, Davey GM, et al. Cutting edge: Enhanced IL-2 signaling can convert self-specific T cell response from tolerance to autoimmunity. J Immunol. 2008;180:5789–93.PubMed
117.
Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113:619–27.PubMed
118.
Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135:3172–7.PubMed
119.
Junghans RP, Stone AL, Lewis MS. Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac) - Evidence for a monomeric structure. J Biol Chem. 1996;271:10453–60.PubMedCrossRef
120.
Jacques Y, Lemauff B, Godard A, et al. Biochemical study of a recombinant soluble interleukin-2 receptor - Evidence for a homodimeric structure. J Biol Chem. 1990;265:20252–8.PubMed
121.
Fisson S, Darrasse-Jeze G, Litvinova E, et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med. 2003;198:737–46.PubMedCrossRef
122.
Klein L, Khazaie K, von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA. 2003;100:8886–91.PubMedCrossRef
123.
Walker LS, Chodos A, Eggena M, et al. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med. 2003;198:249–58.PubMedCrossRef
124.
Robb RJ, Kutny RM. Structure-function relationships for the IL-2-receptor system 4. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol. 1987;139:855–62.PubMed
125.
Kobayashi H, Tagaya Y, Han ES, et al. Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin 2. Cytokine. 1999;11:1065–75.PubMedCrossRef
126.
Kondo N, Kondo S, Shimizu A, et al. A soluble anchorminus interleukin-2 receptor suppresses in vitro interleukin-2-mediated immune responses. Immunol Lett. 1988;19:299–308.PubMedCrossRef
127.
Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R alpha. Proc Natl Acad Sci USA. 2006;103:9166–71.PubMedCrossRef
128.
Treiger BF, Leonard WJ, Svetlik P, et al. A secreted form of the human interleukin-2 receptor encoded by an anchorminus cDNA. J Immunol. 1986;136:4099–105.PubMed
129.
Nervi S, Atlan-Gepner C, Fossat C, et al. Constitutive impaired TCR/CD3-mediated activation of T cells in IDDM patients co-exist with normal co-stimulation pathways. J Autoimmun. 1999;13:247–55.PubMedCrossRef
130.
Lang J, Bellgrau D. A T-cell functional phenotype common among autoimmune-prone rodent strains. Scand J Immunol. 2002;55:546–59.PubMedCrossRef
131.
Granucci F, Vizzardelli C, Pavelka N, et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol. 2001;2:882–8.PubMedCrossRef
132.
Jiang SP, Game DS, Davies D, et al. Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4(+)CD25(+) regulatory T cells? Eur J Immunol. 2005;35:1193–200.PubMedCrossRef
133.
Yui MA, Sharp LL, Havran WL, et al. Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: Subset-specific differences in IL-2 regulation. J Immunol. 2004;172:4691–9.PubMed
134.
Feau S, Facchinetti V, Granucci F, et al. Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice. Blood. 2005;105:697–702.PubMedCrossRef
135.
Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA. 1990;87:7698–702.PubMedCrossRef
136.
Pollard AM, Lipscomb MF. Characterization of murine lung dendritic cells - Similarities to langerhans cells and thymic dendritic cells. J Exp Med. 1990;172:159–67.PubMedCrossRef
137.
Naranjo-Gomez M, Oliva H, Climent N, et al. Expression and function of the IL-2 receptor in activated human plasmacytoid dendritic cells. Eur J Immunol. 2007;37:1764–72.PubMedCrossRef
138.
Mnasria K, Lagaraine C, Velge-Roussel F et al. Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells. J Leukoc Biol. 2008
139.
Matsuda JL, Zhang QJ, Ndonye R, et al. T-bet concomitantly controls migration, survival, and effector functions during the development of V alpha 14i NKT cells. Blood. 2006;107:2797–805.PubMedCrossRef
140.
Henney CS, Kuribayashi K, Kern DE, et al. Interleukin-2 augments natural-killer cell activity. Nature. 1981;291:335–8.PubMedCrossRef
141.
London L, Perussia B, Trinchieri G. Induction of proliferation in vitro of resting human natural-killer cells---IL-2 induces into cell-cycle most peripheral-blood NK cells, but only a minor subset of low-density T cells. J Immunol. 1986;137:3845–54.PubMed
142.
Ortaldo JR, Mason AT, Gerard JP, et al. Effects of natural and recombinant IL-2 on regulation of IFN-gamma production and natural-killer activity - Lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol. 1984;133:779–83.PubMed
143.
Granucci F, Zanoni I, Pavelka N, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med. 2004;200:287–95.PubMedCrossRef
144.
Pericle F, Liu JH, Diaz JI, et al. Interleukin-2 prevention of apoptosis in human neutrophils. Eur J Immunol. 1994;24:440–4.PubMedCrossRef
145.
Djeu JY, Liu JH, Wei S, et al. Function associated with IL-2 receptor-beta on human neutrophils - mechanism of activation of antifungal activity against Candida albicans by IL-2. J Immunol. 1993;150:960–70.PubMed
146.
Girard D, Gosselin J, Heitz D, et al. Effects of interleukin-2 on gene expression in human neutrophils. Blood. 1995;86:1170–6.PubMed
147.
Wei S, Blanchard DK, Liu JH, et al. Activation of tumor-necrosis-factor-alpha production from human neutrophils by IL-2 via IL-2R-beta. J Immunol. 1993;150:1979–87.PubMed
148.
Wei S, Liu JH, Blanchard DK, et al. Induction of IL-8 gene expression in human polymorphonuclear neutrophils by recombinant IL-2. J Immunol. 1994;152:3630–6.PubMed
149.
Jung LKL, Hara T, Fu SM. Detection and functional studies of p60–65 (Tac antigen) on activated human B cells. J Exp Med. 1984;160:1597–602.PubMedCrossRef
150.
Swain SL, Dennert G, Warner JF, et al. Culture supernatants of a stimulated T-cell line have helper activity that acts synergistically with interleukin-2 in the response of B-cells to antigen. Proc Natl Acad Sci USA. 1981;78:2517–21.PubMedCrossRef
151.
Parker DC. Separable helper factors support B-cell proliferation and maturation to Ig secretion. J Immunol. 1982;129:469–74.PubMed
152.
Espinoza-Delgado I, Ortaldo JR, Winklerpickett R, et al. Expression and role of p75 interleukin-2 receptor on human monocytes. J Exp Med. 1990;171:1821–6.PubMedCrossRef
153.
Kniep EM, Strelow I, Lohmannmatthes ML. The monocyte interleukin-2 receptor light chain - production of cell-associated and soluble interleukin-2 receptor by monocytes. Immunology. 1992;75:299–304.PubMed
154.
Valitutti S, Carbone A, Castellino F, et al. The expression of functional IL-2 receptor on activated macrophages depends on the stimulus applied. Immunology. 1989;67:44–50.PubMed
155.
Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. J Immunol. 2006;177:7303–11.PubMed
156.
Cozzolino F, Torcia M, Lucibello M, et al. Interferon-alpha and interleukin-2 synergistically enhance basic fibroblast growth-factor synthesis and induce release, promoting endothelial-cell growth. J Clin Invest. 1993;91:2504–12.PubMedCrossRef
157.
O’Loughlin EV, Pang GP, Noltorp R, et al. Interleukin 2 modulates ion secretion and cell proliferation in cultured human small intestinal enterocytes. Gut. 2001;49:636–43.PubMedCrossRef
158.
Jiang CL, Lu CL. Interleukin-2 and its effects in the central nervous system. Biol Signals Recept. 1998;7:148–56.PubMedCrossRef
Metadata
Title
The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice
Authors
Calliope A. Dendrou
Linda S. Wicker
Publication date
01-11-2008
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 6/2008
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9237-9

Other articles of this Issue 6/2008

Journal of Clinical Immunology 6/2008 Go to the issue

ReviewPaper

Limited T-Cell Receptor Diversity Predisposes to Th2 Immunopathology: Involvement of Tregs and Conventional CD4 T Cells

ReviewPaper

Multiple Sclerosis and Regulatory T Cells

ReviewPaper

Mast Cells and the Adaptive Immune Response

ReviewPaper

Regulation and Privilege in Transplantation Tolerance

ReviewPaper

Molecular Mechanisms of Regulatory T Cell Development

ReviewPaper

Role of Endogenous and Induced Regulatory T Cells During Infections
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits